On June 14, Vladislav Shapsha, the region's Governor, and Oleg Astafurov, Vice President of Government Relations of the Pharmasyntez Group of Companies, signed the relevant documents.

The 3 investment agreements signed at SPIEF-2023 gave rise to a global project:

• The Agreement of Intent to implement projects in the Vorotynsk Industrial Park.

  In the Vorotynsk Industrial Park, the company will launch its largest complex for the production of active pharmaceutical ingredients and finished dosage forms. Nineteen production and auxiliary facilities will be built. Investment in the project will exceed 20 billion rubles. 2,000 jobs will have been created by 2032.

  Already at the first stage, it is planned to build 2 production buildings. Pre-design work is currently underway.

  The relevant cooperation agreements for these projects were signed during the SPIEF:

• On the construction of a plant for the production of active pharmaceutical ingredients by 2026. 4 billion rubles will be invested in the project. 160 jobs will be created.

  The plant will produce both therapeutic and oncological substances (about 60 types each), which will almost completely cover the needs of the Russian healthcare system and will also be exported abroad.

  At present, Pharmasyntez drug substances are produced at the BratskChemSyntez plant. Its volume is about 120 tons per year. It is planned that the Kaluga plant will produce up to 1,000 tons of substances per year.

• On the launch of an enterprise for the production of finished dosage forms by 2026. The investment in the project is about 3.5 billion rubles. The new company will create 200 new jobs.

Oleg Astafurov, Vice President of Government Relations of the Pharmasyntez Group of Companies, pointed out:

“Pharmasyntez has always been one of the largest investors in the Russian pharmaceutical market. Pharmasyntez Group of Companies is committed to providing the country's population with high quality and affordable generic drugs by expanding the cycle of technological conversion for the production of active pharmaceutical ingredients, which allows to significantly reduce the cost of production of pharmaceutical products and thus ensure their greater availability to the healthcare system of the Russian Federation and the country's population”.

“We welcome investors who are willing to strengthen the industry with their technology. Together we can do a lot for the development of the Russian pharmaceutical industry. As a result, millions of people in the country will receive additional quality drug treatment”, – said Vladislav Shapsha, Governor of the Kaluga Region.